Nuwellis (NUWE) announced that the first patient has been treated with the newly launched QUELIMMUNE therapy in a commercial setting at Cincinnati Children’s. QUELIMMUNE, manufactured for SeaStar Medical (ICU) and exclusively licensed and distributed in U.S. pediatric hospitals by Nuwellis, is a novel therapy designed to treat pediatric patientssuffering from acute kidney injury with sepsis or a septic condition and requiring kidney replacement therapy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUWE:
- Nuwellis Announces Equity Offering to Strengthen Finances
- Nuwellis to sell 469,340 shares at $4.24 in registered direct offering
- Nuwellis Announces Pricing of $2.0 Million Offering Priced At-The-Market Under Nasdaq Rules
- Nuwellis, Inc. To Report Second Quarter 2024 Financial Results on August 13, 2024
- Nuwellis Achieves First QUELIMMUNE™ Sale, Cautions Investors